Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis

Duque, Maria Cristina de Oliveira; Vasconcellos, Érica de Camargo Ferreira e; Pimentel, Maria Inês Fernandes; Lyra, Marcelo Rosandiski; Pacheco, Sandro Javier Bedoya; Marzochi, Mauro Célio de Almeida; Rosalino, Cláudia Maria Valete; Schubach, Armando de Oliveira

doi:10.1590/0037-8682-0213-2016

Cited by 22 publications

(34 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…a neglected disease. Meglumine antimoniate (Glucantime) is one of the drugs most used to treat leishmaniasis by recommendation of the World Health Organization (3)(4)(5), even though its mechanisms of action are still unclear and its toxic effects are well known (6,7). Among the main hypotheses on the mechanism of action of meglumine antimoniate, one suggests that Sb V acts as a prodrug, which is metabolized and reduced to its more toxic trivalent form (Sb III ).…”

mentioning

confidence: 99%

Genistein and Ascorbic Acid Reduce Oxidative Stress-Derived DNA Damage Induced by the Antileishmanial Meglumine Antimoniate

Jesus

Soares

Moreira

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Meglumine antimoniate (Glucantime) is a pentavalent antimonial used to treat leishmaniasis, despite its acknowledged toxic effects, such as its ability to cause oxidative damage to lipids and proteins. Recently, our group demonstrated that meglumine antimoniate causes oxidative stress-derived DNA damage. Knowing that antioxidants modulate reactive oxygen species, we evaluated the capacity of genistein and ascorbic acid for preventing genotoxicity caused by meglumine antimoniate. For that, mice (n= 5/group) received genistein (via gavage) in doses of 5, 10, and 20 mg/kg for three consecutive days. After this period, they were treated with 810 mg/kg meglumine antimoniate via intraperitoneal (i.p.) route. Furthermore, mice (n= 5/group) simultaneously received ascorbic acid (i.p.) in doses of 30, 60, and 120 mg/kg and 810 mg/kg meglumine antimoniate. We also conducted post- and pretreatment assays, in which animals received ascorbic acid (60 mg/kg) 24 h prior to or after receiving meglumine antimoniate. Genomic instability and mutagenicity were analyzed through conventional comet assay and enzymatic assay using formamide pyrimidine DNA glycosylase (Fpg) enzyme, as well as the micronucleus test, respectively. Meglumine antimoniate induced an increase in the DNA damage after digestion with Fpg, reinforcing its mutagenic potential by oxidizing DNA bases, which was prevented by genistein. Similarly, ascorbic acid was capable of reducing mutagenic effects in simultaneous treatment as well as in posttreatment. Therefore, our results demonstrate that both compounds are efficient in preventing mutations in mammalian cells treated with meglumine antimoniate.

show abstract

mentioning

confidence: 99%

Genistein and Ascorbic Acid Reduce Oxidative Stress-Derived DNA Damage Induced by the Antileishmanial Meglumine Antimoniate

Jesus

Soares

Moreira

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Intralesional meglumine antimoniate administration has been used as a therapeutic alternative in patients who have contraindications for systemic treatment; however, its true efficacy has not been established. For approximately 30 years, intralesional meglumine antimoniate administration has been compared in literature to other local methods, such as intralesional sodium stibogluconate 8 , zinc sulfate, topical paromomycin 9 , trichloroacetic acid, and cryotherapy 10 , or its efficacy and safety was retrospectively described 11 .…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series

Arboleda

Barrantes

Usuga

et al. 2019

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine antimoniate administration has fewer adverse effects and can be as effective and safe. We describe 12 patients treated with intralesional meglumine antimoniate: seven with primary and five with recurrent lesions. The majority (11/12) met all cure criteria after 1-7 sessions of meglumine antimoniate administration (1-5 mL). Adverse effects comprised mainly of local pain and edema. Intralesional meglumine antimoniate administration could be an excellent alternative treatment for uncomplicated CL; however, controlled clinical trials are needed to test the efficacy and safety thereof.

show abstract

“…Immunocompetent patients, those with a single cutaneous lesion of less than 3 cm, not located on a joint or facial area and that are not superinfected, are the best candidates for local therapy [4,23].…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment with Intralesional Meglumine Antimoniate in Recurrent Cutaneous Leishmaniasis: Case Report

Vivas

Vidal

et al. 2017

JDC

View full text Add to dashboard Cite

A case of a pediatric patient with a recurrent single lesion, four months after finishing treatment for seven lesions of cutaneous leishmaniasis with intramuscular meglumine antimoniate. Once the recurrence was confirmed by direct visualization of amastigotes, the decision taken was to repeat treatment with 1 cc of intralesional meglumine antimoniate, with a uniform distribution inside the lesion and one week interval between each application. After four sessions of intralesional treatment, the patient meets curation criteria. The patient was discharged with follow-up appointment up to seven months after the treatment was finished, there was no evidence of recurrence.

show abstract

Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis

Cited by 22 publications

References 3 publications

Genistein and Ascorbic Acid Reduce Oxidative Stress-Derived DNA Damage Induced by the Antileishmanial Meglumine Antimoniate

Genistein and Ascorbic Acid Reduce Oxidative Stress-Derived DNA Damage Induced by the Antileishmanial Meglumine Antimoniate

Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series

Successful Treatment with Intralesional Meglumine Antimoniate in Recurrent Cutaneous Leishmaniasis: Case Report

Contact Info

Product

Resources

About